Search

Your search keyword '"Yunyun Zeng"' showing total 2 results
Start Over Author "Yunyun Zeng" Journal plos one
2 results on '"Yunyun Zeng"'

1. Sequence-dependent antiproliferative effects of gefitinib and docetaxel on non-small cell lung cancer (NSCLC) cells and the possible mechanism.

Author

Bei Chen, Jingxian Zheng, Yunyun Zeng, Baofeng Li, Bo Xie, Jihua Zheng, Juan Zhou, and Weimin Zhang

Subjects
Medicine, Science
Abstract

PURPOSE: Recent clinical trials showed that the sequential combination of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy could prolong the PFS and/or OS of advanced non-small cell lung cancer (NSCLC) patients with EGFR mutation. The aim of present study was to assess the optimal combination sequence and to explore its possible mechanism. METHODS: PC-9 cells and A549 cells, the lung adenocarcinoma cells with mutant and wide-type EGFR respectively, were treated with docetaxel/gefitinib alone or in different combination schedules. The EGFR and K-ras gene status was determined by qPCR-HRM technique. Cell proliferation was detected by MTT assay. The expression and phosphorylation of EGFR, ERK, Akt and IGF-1R were detected by western blot. Cell cycle distribution was observed by flow cytometry. RESULTS: Only sequential administration of docetaxel followed by gefitinib (D → G) induced significant synergistic effect in both cell lines (Combination Index1.1), whereas the concurrent administration (D+G) showed additive (0.9

Published
2014
Full Text
View/download PDF

2. Sequence-Dependent Antiproliferative Effects of Gefitinib and Docetaxel on Non-Small Cell Lung Cancer (NSCLC) Cells and the Possible Mechanism

Author

Juan Zhou, Yunyun Zeng, Baofeng Li, Bo Xie, Jihua Zheng, Jingxian Zheng, Weimin Zhang, and Bei Chen

Subjects
MAPK/ERK pathway, Lung Neoplasms, Pulmonology, Cancer Treatment, lcsh:Medicine, non-small cell lung cancer (NSCLC), Docetaxel, Pharmacology, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Medicine and Health Sciences, Cell Cycle and Cell Division, Phosphorylation, lcsh:Science, Chemotherapeutic Agents, Multidisciplinary, Cell Cycle, Gefitinib, Combination chemotherapy, Cell cycle, ErbB Receptors, Oncology, Cell Processes, Taxoids, Oncology Agents, Cancer Prevention, Research Article, medicine.drug, MAP Kinase Signaling System, Antineoplastic Agents, Chemoprevention, Drug Administration Schedule, Cell Line, Tumor, medicine, Humans, Protein Kinase Inhibitors, neoplasms, Cell Proliferation, A549 cell, Cell growth, business.industry, lcsh:R, Biology and Life Sciences, Cell Biology, medicine.disease, respiratory tract diseases, Genes, ras, Quinazolines, lcsh:Q, Clinical Medicine, business
Abstract

PURPOSE: Recent clinical trials showed that the sequential combination of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy could prolong the PFS and/or OS of advanced non-small cell lung cancer (NSCLC) patients with EGFR mutation. The aim of present study was to assess the optimal combination sequence and to explore its possible mechanism. METHODS: PC-9 cells and A549 cells, the lung adenocarcinoma cells with mutant and wide-type EGFR respectively, were treated with docetaxel/gefitinib alone or in different combination schedules. The EGFR and K-ras gene status was determined by qPCR-HRM technique. Cell proliferation was detected by MTT assay. The expression and phosphorylation of EGFR, ERK, Akt and IGF-1R were detected by western blot. Cell cycle distribution was observed by flow cytometry. RESULTS: Only sequential administration of docetaxel followed by gefitinib (D → G) induced significant synergistic effect in both cell lines (Combination Index1.1), whereas the concurrent administration (D+G) showed additive (0.9

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results